Success of intravenous immunoglobulin and steroids in managing severe COVID-19 following lung transplantation: A case report.

Yen-Shou Kuo, Kuan-Hsun Lin, Ying-Yi Chen, Yuan-Ming Tsai, Ti-Hui Wu, Hsu-Kai Huang, Tsai-Wang Huang
{"title":"Success of intravenous immunoglobulin and steroids in managing severe COVID-19 following lung transplantation: A case report.","authors":"Yen-Shou Kuo, Kuan-Hsun Lin, Ying-Yi Chen, Yuan-Ming Tsai, Ti-Hui Wu, Hsu-Kai Huang, Tsai-Wang Huang","doi":"10.5500/wjt.v15.i1.96696","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) pneumonia with severe septic shock and acute respiratory distress syndrome (ARDS) are critical illnesses for patients following transplant. Intravenous immunoglobulin (IVIG) plays a role in both immune support and inflammation control, especially in immunocompromised patients. This case report describes the first successful experience using IVIG and pulse steroids to manage this critical condition following lung transplantation.</p><p><strong>Case summary: </strong>A 65-year-old male patient reported a history of chronic obstructive pulmonary disease and poor lung function and received bilateral sequential lung transplantations. Postoperatively, he developed COVID-19 pneumonia, severe septic shock, and ARDS. He recovered from this critical condition after empirical antibiotics administration and veno-venous extracorporeal membrane oxygenation, in addition to IVIG and pulse steroids.</p><p><strong>Conclusion: </strong>IVIG is a valuable adjunct in managing severe sepsis in lung transplant recipients after COVID-19 infection. We aim, for the first time, to report the success of such a management approach for COVID-19 ARDS and sepsis in the post-lung transplant setting. With further investigations, this is a starting point for wider analysis of such an approach in this setting and consequently helps guide clinical practice for such a challenging patient population moving forward.</p>","PeriodicalId":65557,"journal":{"name":"世界移植杂志","volume":"15 1","pages":"96696"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612894/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"世界移植杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5500/wjt.v15.i1.96696","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Coronavirus disease 2019 (COVID-19) pneumonia with severe septic shock and acute respiratory distress syndrome (ARDS) are critical illnesses for patients following transplant. Intravenous immunoglobulin (IVIG) plays a role in both immune support and inflammation control, especially in immunocompromised patients. This case report describes the first successful experience using IVIG and pulse steroids to manage this critical condition following lung transplantation.

Case summary: A 65-year-old male patient reported a history of chronic obstructive pulmonary disease and poor lung function and received bilateral sequential lung transplantations. Postoperatively, he developed COVID-19 pneumonia, severe septic shock, and ARDS. He recovered from this critical condition after empirical antibiotics administration and veno-venous extracorporeal membrane oxygenation, in addition to IVIG and pulse steroids.

Conclusion: IVIG is a valuable adjunct in managing severe sepsis in lung transplant recipients after COVID-19 infection. We aim, for the first time, to report the success of such a management approach for COVID-19 ARDS and sepsis in the post-lung transplant setting. With further investigations, this is a starting point for wider analysis of such an approach in this setting and consequently helps guide clinical practice for such a challenging patient population moving forward.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
静脉注射免疫球蛋白和类固醇成功控制了肺移植后的严重 COVID-19:病例报告。
背景:2019冠状病毒病(COVID-19)肺炎合并严重脓毒性休克和急性呼吸窘迫综合征(ARDS)是移植术后患者的危重疾病。静脉注射免疫球蛋白(IVIG)在免疫支持和炎症控制中发挥着重要作用,特别是在免疫功能低下的患者中。本病例报告描述了首次成功使用IVIG和脉冲类固醇治疗肺移植后这种危急情况的经验。病例总结:65岁男性患者,有慢性阻塞性肺疾病病史,肺功能差,接受双侧序贯肺移植。术后出现COVID-19肺炎、严重感染性休克、ARDS。经经验性抗生素治疗和静脉-静脉体外膜氧合,以及IVIG和脉冲类固醇治疗后,他从这种危急情况中恢复过来。结论:IVIG是治疗COVID-19感染后肺移植术后严重脓毒症的一种有价值的辅助手段。我们的目标是首次报告这种管理方法在肺移植后环境中对COVID-19 ARDS和败血症的成功。随着进一步的研究,这是在这种情况下对这种方法进行更广泛分析的起点,从而有助于指导这种具有挑战性的患者群体的临床实践。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
293
期刊最新文献
Clinical impact of early graft function in kidney transplant recipients on long-term dialysis: A retrospective cohort study. Systematic review and meta-analysis of the role of aorto-hepatic conduits in liver transplant: Known knowns and known unknowns. Comparison of Clavien-Dindo classification and comprehensive complication index in patients undergoing simultaneous pancreas-kidney transplantation. Clinical characteristics and outcomes of keratoplasty in moderate to severe infective corneal ulcers. Towards curing type 1 diabetes: Prospects and challenges of allogeneic or xenogeneic donor islet cell transplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1